Mortality, Complications With Therapeutic Plasma Exchange for Acute Immune TTP
Although 76% of patients reported experiencing complications during treatment, the mortality rate per episode was only 3.7%.
Thrombotic Thrombocytopenic Purpura
Risk Factors for In-Hospital Mortality Among Younger Patients With TTP
Younger age, male sex, and African American ethnicity were found to be independent predictors of in-hospital mortality in younger patients with TTP.
Acquired TTP and Septic Disseminated Intravascular Coagulation Distinguishable With Lab Tests
Severe thrombocytopenia, antithrombin levels, and degree of fibrinogen degradation product elevation were found to be distinguishing factors of aTTP.
Elderly Patients With Immune Thrombotic Thrombocytopenic Purpura at Increased Risk for Mortality
Elderly patients with immune thrombotic thrombocytopenia purpura often have atypical presentation, which can delay diagnosis and treatment.
Blood Type as a Predictor of Response to Therapeutic Plasma Exchange in Thrombotic Thrombocytopenic Purpura
Of patients with ADAMTS13 deficiency, those who had type O blood underwent fewer therapeutic plasma exchange procedures compared with patients with type A or B blood.
Caplacizumab Safe, Efficacious With Exacerbation of Acquired Thrombotic Thrombocytopenic Purpura
Researchers evaluated the safety and efficacy of open-label caplacizumab in patients who experienced disease exacerbation during blinded treatment.
Relapse Delayed But Not Prevented With Rituximab for Immune TTP
Patients treated with rituximab experienced improved relapse-free survival at 1 and 3 years but not 5 years after treatment compared with patients receiving corticosteroids alone.
Mental Health Impairment in Acute Thrombotic Thrombocytopenic Purpura
At a median follow-up of 36 months, patients with acute thrombotic thrombocytopenic purpura displayed impaired quality of life compared with the general population.
Risk of Stroke Following an Episode of Acute TTP Seen With Low ADAMTS13 Activity
Stroke occurred in no patients with normal ADAMTS13 activity but did occur in 27.6% of patients with ADAMTS13 activity below 70%, the cutoff for normal activity.
VWF High-Molecular-Weight Multimer Deficiency Associated With Neurological Symptoms in TTP
Researchers assessed whether loss of von Willebrand factor high-molecular-weight multimers was predictive of morbidity in thrombotic thrombocytopenic purpura.
Next post in Thrombotic Disorders
